Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 28 2025
0mins
Source: Newsfilter
Company Delisting Announcement: Syros Pharmaceuticals has announced its intention to voluntarily delist its common stock from the Nasdaq Stock Market and deregister under the Securities Exchange Act due to non-compliance with listing standards and to preserve cash for an orderly wind-down of operations.
Impact of Failed Trial: The decision follows the failure of the Company's SELECT-MDS-1 Phase 3 trial, which resulted in a default under a loan agreement, prompting the Board to limit expenditures and focus on maximizing cash for stakeholders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
